RCEL (AVITA Medical) Quality Rank

View and export this data going back to 2012. Start your Free Trial

What is AVITA Medical Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

AVITA Medical Quality Rank Related Terms

Thank you for viewing the detailed overview of AVITA Medical's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AVITA Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AVITA Medical Inc (NAS:RCEL) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

AVHHL:USA 51KA:Germany 51KA:Germany 51KB:Germany AVH:Australia

Address

28159 Avenue Stanford, Suite 220, Valencia, Santa Clarita, CA, USA, 91355

Website

https://www.avitamedical.com

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Executives

Robert Mcnamara	director	C/O LDR HOLDING CORPORATION, 13785 RESEARCH BOULEVARD, SUITE 200, AUSTIN TX 78750
David D O'toole	officer: CFO	1640 MARENGO STREET, LOS ANGELES CA 90033
Suzanne Crowe	director	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
James Corbett	director	2 GOODYEAR, IRVINE CA 92618
Jeremy Curnock Cook	director	TARGETED GENETICS CORP, 1100 OLIVE WAY STE 100, SEATTLE WA 98101
Donna Shiroma	officer: General Counsel	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Cary Guy Vance	director	800 EAST MIDDLEFIELD RD, MOUNTAIN VIEW CA 94043
Michael S Perry	director, officer: Chief Executive Officer	C/O BIOTRANSPLANT INC, 196 BOSTON AVE SUITE 2800, MEDFORD MA 02155
Jan Stern Reed	director	C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Michael Holder	officer: Chief Financial Officer	6170 RESEARCH RD., STE 103, FRISCO TX 75034
Kathy M. Mcgee	officer: Chief Operating Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Sean Ekins	officer: Sr. VP of Finance	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
David Mcintyre	officer: Chief Financial Officer	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000
Erin Liberto	officer: Chief Commercial Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355
Andrew Quick	officer: Chief Technology Officer	C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 200, VALENCIA CA 91355